Borozdin Wiktor, Bravo Ferrer Acosta Ana M, Bamshad Michael J, Botzenhart Elke M, Froster Ursula G, Lemke Johannes, Schinzel Albert, Spranger Stephanie, McGaughran Julie, Wand Dorothea, Chrzanowska Krystyna H, Kohlhase Jürgen
Institut für Humangenetik und Anthropologie, Universität Freiburg, Freiburg, Germany.
Hum Mutat. 2006 Sep;27(9):975-6. doi: 10.1002/humu.9449.
Mutations in the gene TBX5 cause Holt-Oram syndrome (HOS), an autosomal dominant disorder characterized by anterior (i.e., radial ray) upper limb malformations and congenital heart defects and/or cardiac conduction anomalies. The detection rate for TBX5 mutations in HOS patients has been given as 30-35% in most reports. However, a detection rate of 74% was reported when strict clinical inclusion criteria for HOS were applied prior to TBX5 analysis. Still, in a significant proportion of typical HOS cases no mutation can be found within the TBX5 coding region and flanking intronic sequences. One explanation could be that large but submicroscopic deletions of TBX5 could cause HOS, yet only one such TBX5 deletion has been reported to date. We developed a quantitative Real Time PCR strategy to detect large, submicroscopic deletions in TBX5. Using this assay, we screened a total of 102 TBX5 mutation negative patients and discovered two novel intragenic deletions. One deletion of 7756 bp removes exon 6 and a considerable part of the neighboring intronic sequences, and the other of 3695 bp removes exon 9 with the stop codon and the 3'UTR completely as well as a part of the preceding intron 8. We conclude that quantitative Real Time PCR is a reliable method to detect submicroscopic deletions within TBX5. However, such deletions explain only approximately 2% of the TBX5 mutational spectrum in HOS cases. In addition, we also present eight novel TBX5 mutations (three nonsense, one splice mutation, four short deletions) as detected by direct sequencing in 21 families not previously analyzed for mutations.
TBX5基因的突变会导致霍尔特-奥拉姆综合征(HOS),这是一种常染色体显性疾病,其特征为上肢前部(即桡骨射线)畸形以及先天性心脏缺陷和/或心脏传导异常。在大多数报告中,HOS患者中TBX5突变的检出率为30%-35%。然而,在进行TBX5分析之前应用严格的HOS临床纳入标准时,报告的检出率为74%。尽管如此,在相当一部分典型的HOS病例中,在TBX5编码区和侧翼内含子序列中未发现突变。一种解释可能是TBX5的大片段但亚显微缺失可能导致HOS,但迄今为止仅报道了一例此类TBX5缺失。我们开发了一种定量实时PCR策略来检测TBX5中的大片段亚显微缺失。使用该检测方法,我们共筛查了102例TBX5突变阴性患者,发现了两个新的基因内缺失。一个7756 bp的缺失去除了外显子6和相邻内含子序列的相当一部分,另一个3695 bp的缺失完全去除了带有终止密码子的外显子9和3'UTR以及前一个内含子8的一部分。我们得出结论,定量实时PCR是检测TBX5内亚显微缺失的可靠方法。然而,此类缺失仅解释了HOS病例中TBX5突变谱的约2%。此外,我们还展示了通过直接测序在之前未进行突变分析的21个家族中检测到的8个新的TBX5突变(3个无义突变、1个剪接突变、4个短缺失)。